Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trandolaprilat SCHEMBL156829 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL11076552 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL678354 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5567196 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173132 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173121 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL11286342 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5794079 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173113 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL7388097 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | OHIO STATE INNOVATION FOUNDATION (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | TRANSLATUM MEDICUS INC (CA) | 2026-01-08 | — | — | US | disclosed |
| US-20250387449-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2025-12-25 | — | — | US | disclosed |
| EP-4662203-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2025-12-17 | — | — | EP | disclosed |
| EP-3956813-B1 | DETECTION, PREDICTION, AND CLASSIFICATION FOR OCULAR DISEASE | TRACERY OPHTHALMICS INC (CA) | 2025-11-26 | — | — | EP | disclosed |
| US-12377171-B2 | Methods for treating and diagnosing blinding eye diseases | Translatum Medicus Inc. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | OHIO STATE INNOVATION FOUNDATION (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250152781-A1 | TISSUE ENGINEERING AND DRUG DELIVERY DEVICE | OHIO STATE INNOVATION FOUNDATION | 2025-05-15 | — | — | US | disclosed |
| US-20240335585-A1 | TISSUE-ENGINEERED SCAFFOLDS AND METHODS OF MAKING | GEORGIA TECH RESEARCH CORPORATION | 2024-10-10 | — | — | US | disclosed |
| US-20220207729-A1 | DETECTION, PREDICTION, AND CLASSIFICATION FOR OCULAR DISEASE | TRACERY OPHTHALMICS INC. (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20220117888-A1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| US-20220118159-A1 | ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| EP-3956813-A1 | DETECTION, PREDICTION, AND CLASSIFICATION FOR OCULAR DISEASE | Boyd, Shelley (CA) | 2022-02-23 | — | — | EP | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-5225401-A | Endopeptidase inhibitors for congestive heart failure | E. R. SQUIBB & SONS, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0527624-A2 | Use of a selective inhibitor of neutral endopeptidase and an angiotensin converting enzyme inhibitor in the preparation of a pharmaceutical for treating congestive heart failure | E.R. Squibb & Sons, Inc. (US) | 1993-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | ARG1, ARG2, PDE6D | ACE 3556/4885MEN1 2591/4885KMT2A 3583/4885 |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | AGER, ALDH1A2, RBP1 | ACE 1283/4885MEN1 3538/4885KMT2A 4305/4885 |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | PDE6C, CHMP4B, PDE6D | ACE 1928/4885MEN1 1122/4885KMT2A 4733/4885 |
| US-20250387449-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | SLC10A2, SLC10A1, ABCB11 | ACE 2964/4885MEN1 3166/4885KMT2A 1813/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885MEN1 3647/4885KMT2A 2044/4885 |
| US-12377171-B2 | Methods for treating and diagnosing blinding eye diseases | ALDH1A2, RBP1, RBP4 | ACE 220/4885MEN1 4428/4885KMT2A 4415/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885MEN1 1910/4885KMT2A 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.